The Integrin Alpha 4 Beta 1 (VLA-4) as a Therapeutic Target
The Integrin Alpha 4 Beta 1 (VLA-4) as a Therapeutic Target
复制标题
整合素 Alpha 4 Beta 1 (VLA-4) 作为治疗靶点
DOI：
--
复制
发表时间：
1995
期刊：
影响因子：
--
通讯作者：
Elices Mj
中科院分区：
文献类型：
--
作者：
Elices Mj
动物疾病模型表明，白细胞整合素α4β1(VLA-4)是治疗许多慢性炎症性疾病的合适靶点。虽然体内研究集中在使用抗α4抗体作为概念验证工具，但反复给药来对抗人类慢性炎症很可能需要小的α4β1拮抗剂。我们已经开发出低分子量的α4β1抑制剂，已在慢性炎症动物模型中显示出治疗前景。
Disease models in animals demonstrate that the leukocyte integrin alpha 4 beta 1 (VLA-4) is a suitable target for therapy in a number of chronic inflammatory disorders. While in vivo studies have concentrated on the use of anti-alpha 4 antibodies as proof of concept tools, repeated administration to combat human chronic inflammatory conditions is likely to require small antagonists of alpha 4 beta 1. We have developed low molecular weight alpha 4 beta 1 inhibitors which have shown therapeutic promise in animal models of chronic inflammation.